Every 424B that Inspira Technologies Oxy B.H.N. Ltd. (IINN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow IINN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IINN filings page.
Inspira Technologies Oxy B.H.N. Ltd. is offering up to $2,015,985 of ordinary shares through an at-the-market program with A.G.P./Alliance Global Partners under its existing $75 million shelf registration.
The ATM facility lets the company sell shares on Nasdaq from time to time at prevailing prices, paying A.G.P. a 3% commission. Shares outstanding were 43,271,837 as of February 17, 2026, and would rise to 46,694,562 if the full amount were sold at $0.589 per share. The company plans to use net proceeds for research and development, regulatory work, commercialization and general corporate purposes.
The filing highlights substantial dilution for new investors, Nasdaq non-compliance with the $1.00 minimum bid price rule, and an auditor’s going concern paragraph, underscoring financing and listing risks alongside the capital raise.
Inspira Technologies Oxy B.H.N. Ltd. is registering 6,785,715 ordinary share equivalents through a direct offering of 4,000,000 ordinary shares and pre-funded warrants to purchase up to 2,785,715 additional shares at combined prices around $0.70 per paired security and warrant.
In a concurrent private placement, the same investor will receive unregistered warrants to purchase up to 6,785,715 ordinary shares at an exercise price of $0.70, exercisable six months after issuance for five and a half years. The transaction is expected to generate gross proceeds of $4,749,721 and approximately $4.3 million in net proceeds, which the company plans to use for working capital and general corporate purposes.
Ordinary shares outstanding are expected to increase from 37,074,123 to 43,859,838 assuming full exercise of the pre-funded warrants, resulting in meaningful dilution for existing shareholders. The company also agreed to reduce the exercise price and extend the term of 3,031,250 existing warrants, further expanding potential future share issuance.
Inspira Technologies Oxy B.H.N. Ltd. is offering 1,565,217 ordinary shares in a registered direct offering to a single institutional and accredited investor at $1.15 per share. The company expects net proceeds of approximately $1.7 million, which it plans to use for working capital and general corporate purposes.
Ordinary shares outstanding were 34,150,987 as of December 11, 2025, and are expected to be 35,716,204 after the offering. Inspira is a specialty medical device company developing life support technologies, including its FDA‑cleared INSPIRA ART100 cardiopulmonary bypass system, the investigational INSPIRA ART respiratory support platform, and the HYLA blood sensor.
The prospectus highlights significant risks, including a going concern explanatory paragraph in its 2024 audited financial statements, potential dilution from future equity issuances, share price volatility, and dependence on maintaining Nasdaq listing requirements. The company also notes operational and geopolitical risks related to its primary operations in Israel amid regional conflicts.